Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01434290 · ClinicalTrials.gov registry record · Phase 2

Radiation Therapy in Treating Patients With Prostate Cancer

A Phase 2 study, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 2
Development phase
255
Enrollment target

NCT01434290 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 255 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01434290, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
255 participants
Enrollment target

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Given radiation therapy in different ways may kill more tumor cells. PURPOSE: This randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.

Interventions

  • RADIATION 36.25 Gy IMRT
  • RADIATION 51.6 Gy IMRT

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2011-09
Est. Completion 2022-05-20
Phase Phase 2

Sponsor

Radiation Therapy Oncology Group

144 total trials

What the Registry Record Tells You About NCT01434290

The ClinicalTrials.gov registry entry for NCT01434290 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which 36.25 Gy IMRT is the first listed.

NCT01434290 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01434290 about?

NCT01434290 is a clinical study titled "Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Given radiation therapy in different ways may kill more tumor cells. ...

What is the current status of trial NCT01434290?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2011-09. Estimated completion is 2022-05-20.

What interventions are being tested in trial NCT01434290?

The interventions under investigation include: 36.25 Gy IMRT (RADIATION), 51.6 Gy IMRT (RADIATION).

Who is sponsoring clinical trial NCT01434290?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.